Sanofi expands KT-474 Phase 2 trials in HS and AD after positive interim data review

Kymera Therapeutics, Inc.

Sanofi to expand ongoing Phase 2 trials for KT-474 in hidradenitis suppurativa and atopic dermatitis.
Expansion follows interim safety and efficacy review by an Independent Data Review Committee.
Move intended to accelerate timelines and progress toward pivotal registrational studies.
Kymera CEO Nello Mainolfi cites potential to address large unmet needs with high market potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.